NCT02470702View on ClinicalTrials.gov

Multiple Oritavancin Doses on Safety, Tolerability, and Pharmacokinetics in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

June 30, 2015

Primary Completion Date

October 31, 2015

Study Completion Date

October 31, 2015

Conditions
Healthy
Interventions
DRUG

Oritavancin

DRUG

Placebo (D5W)

Trial Locations (1)

53095

West Bend

Sponsors
All Listed Sponsors
lead

Melinta Therapeutics, Inc.

INDUSTRY